Butorphanol Tartrate

CHEMBL299400 Phase 4 已批准 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

477.5 g/mol

LogP

—

Phase

4

The tartrate salt of butorphanol, a mixed opioid analgesic with agonist activity at kappa receptors and antagonist-to-partial-agonist activity at mu receptors. The nasal spray formulation offers a convenient non-injectable route for pain and migraine management. Psychotomimetic side effects such as dysphoria and hallucinations can occur.

分子量

477.5000 g/mol

TPSA

159.00 Å²

治疗领域

Pain Management Generalized Anxiety Disorder Chronic Pain

作用机制

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

二维结构

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C(O)C(O)C(O)C(=O)O.Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3

InChI

InChI=1S/C21H29NO2.C4H6O6/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15;5-1(3(7)8)2(6)4(9)10/h6-7,13,15,19,23-24H,1-5,8-12,14H2;1-2,5-6H,(H,7,8)(H,9,10)/t19-,20+,21-;/m1./s1

Molecular Formula

C25H35NO8

HBD / HBA

6 / 9

可旋转键数

5

重原子数

34

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

The tartrate salt of butorphanol, a mixed opioid analgesic with agonist activity at kappa receptors and antagonist-to-partial-agonist activity at mu receptors. The nasal spray formulation offers a convenient non-injectable route for pain and migraine management. Psychotomimetic side effects such as dysphoria and hallucinations can occur.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Butorphanol Tartrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL299400. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5464090. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

正在寻找患者友好型信息？

Butorphanol Tartrate 在 PillFYI 上

结构

快速数据

分子式: C25H35NO8
同义词: 4

外部链接

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.